NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

Seth M. Pollack*, Achim A. Jungbluth, Benjamin L. Hoch, Erik A. Farrar, Marie Bleakley, David J. Schneider, Elizabeth T. Loggers, Eve Rodler, Janet F. Eary, Ernest U. Conrad, Robin L. Jones, Cassian Yee

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

BACKGROUND: Myxoid/round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for >33% of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY-ESO-1 is a cancer-testis antigen (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors. METHODS: The authors investigated the feasibility of targeting NY-ESO-1 in patients with MRCL by evaluating the prevalence of NY-ESO-1 expression in tumors using immunohistochemistry and quantitative reverse transcriptase-polymerase chain reaction analysis. NY-ESO-1-specific tumor recognition by NY-ESO-1-specific T-cells also was analyzed using a chromium release assay. RESULTS: A search of the University of Washington Sarcoma Tissue Bank identified paraffin-embedded tumor samples from 25 patients with MRCL. NY-ESO-1 expression was observed in every MRCL tumor assessed (100%); in 18 tumors (72%), staining was homogenous. In all but 2 tumors, staining was sufficiently robust (2+) that such patients would be eligible for clinical trials of NY-ESO-1-directed therapy. By using NY-ESO-1 specific, CD8-positive T-cells, the in vitro sensitivity of myxoid liposarcoma cell lines to antigen-specific lysis was demonstrated. CONCLUSIONS: The current results establish NY-ESO-1 as an important target antigen for the treatment of patients with MRCL. Cancer 2012. © 2012 American Cancer Society. The authors demonstrate that the cancer-testis antigen NY-ESO-1 is expressed in 100% of myxoid/round cell liposarcoma (MRCL) tumors tested and that MRCL cell lines can be recognized and specifically lysed by NY-ESO-1-specific effectors in vitro. These results establish NY-ESO-1 as an important target antigen for the treatment of patients with MRCL.

Original languageEnglish (US)
Pages (from-to)4564-4570
Number of pages7
JournalCancer
Volume118
Issue number18
DOIs
StatePublished - Sep 15 2012
Externally publishedYes

Keywords

  • NY-ESO-1
  • cancer testis antigens
  • immunotherapy
  • myxoid
  • sarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma'. Together they form a unique fingerprint.

Cite this